Known targets — ChEMBL curated mechanism
MTORPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5
The experimentally established mechanism targets of Apitolisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA known ✓ | P42336 | 20/20 | 1.00 |
| ▸ | PIK3CD known ✓ | O00329 | 14/20 | 1.00 |
| ▸ | MTOR known ✓ | P42345 | 11/20 | 1.00 |
| ▸ | PIK3CB known ✓ | P42338 | 11/20 | 1.00 |
| ▸ | PIK3CG known ✓ | P48736 | 10/20 | 1.00 |
| ▸ | PIK3R1 known ✓ | P27986 | 1/20 | 0.56 |
| ▸ | PIK3C2A | O00443 | 1/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | PAK4 | O96013 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | FGR | P09769 | 1/20 | 1.00 |
| ▸ | FER | P16591 | 1/20 | 1.00 |
| ▸ | PRKCA | P17252 | 1/20 | 1.00 |
| ▸ | JAK1 | P23458 | 1/20 | 1.00 |
| ▸ | TEC | P42680 | 1/20 | 1.00 |
| ▸ | SYK | P43405 | 1/20 | 1.00 |
| ▸ | PRKDC | P78527 | 1/20 | 1.00 |
| ▸ | MAP3K9 | P80192 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apitolisib SCHEMBL31270275 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| Apitolisib SCHEMBL29447291 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| Apitolisib SCHEMBL1180678 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| Apitolisib SCHEMBL466298 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL1182231 | 0.94 | PIK3CA (1.00) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL1181040 | 0.94 | PIK3CA (1.00) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL1181037 | 0.94 | PIK3CA (1.00) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL11985345 | 0.94 | PIK3CA (0.88) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL1180941 | 0.92 | PIK3CA (0.85) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL1180938 | 0.92 | PIK3CA (0.85) | PIK3CAPIK3CDMTORPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3354 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122028938-A | Pharmaceutical combination comprising an anti-CD 37 antibody maytansinoid conjugate and a BCL2 inhibitor or PI3K inhibitor | 德彪药业国际股份公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4729121-A2 | NOVEL COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DERMAL DISORDERS | Drexel University (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| US-20260083752-A1 | PHARMACEUTICAL METHODS, COMPOSITIONS AND COMBINATIONS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2026-03-26 | — | — | US | claimed |
| US-12576069-B2 | Compositions and methods for treating slow-flow vascular malformations | YALE UNIVERSITY (US) | 2026-03-17 | — | — | US | claimed |
| US-20260057961-A1 | CHROMOSOME 9P24 LOSS AND GAIN PREDICTS RESISTANCE AND BENEFIT OF IMMUNE CHECKPOINT INHIBITORS | UNIV CALIFORNIA (US) | 2026-02-26 | — | — | US | claimed |
| EP-4698175-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-02-25 | — | — | EP | claimed |
| US-20260041692-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | SOVARGEN CO LTD (KR) | 2026-02-12 | — | — | US | claimed |
| US-20110097349-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-28 | — | — | US | claimed |
| US-7888352-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIRAMED LIMITED (GB) | 2011-02-15 | — | — | US | claimed |
| US-20100233164-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | GENENTECH, INC. | 2010-09-16 | — | — | US | claimed |
| WO-2010105008-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | GENENTECH, INC. (US) | 2010-09-16 | — | — | WO | claimed |
| EP-2205242-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | Genentech, Inc. (US) | 2010-07-14 | — | — | EP | claimed |
| EP-2114949-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2009-11-11 | — | — | EP | claimed |
| US-20090098135-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. | 2009-04-16 | — | — | US | claimed |
| WO-2009036082-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2009-03-19 | — | — | WO | claimed |
| US-20080242665-A1 | 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-02 | — | — | US | claimed |
| WO-2008070740-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | claimed |